Paper Details

  1. Home
  2. Paper Details

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.

Author: AliS M, AminH M, BalusuR, BehrangA, GangulyS, HegdeA, IyerS, JensenR A, KuraviS, MadisonR W, McGuirkJ P, MushtaqM U, SubbiahV, VenstromJ M, VivianC J, WelchD R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Ceritinib, a drug that targets the ALK fusion kinase, showed promising preclinical and clinical efficacy in treating NPM1-ALK+ ALCL. In vitro studies showed that ceritinib inhibited the activity of the fusion kinase and induced apoptosis in lymphoma cell lines. In a xenograft model, ceritinib led to tumor regression and improved survival. A patient with multiple relapses of NPM1-ALK+ ALCL achieved complete remission with ongoing clinical benefit after receiving ceritinib treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: More than 80% of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated the preclinical and clinical efficacy of ceritinib treatment of this aggressive lymphom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271116/

データ提供：米国国立医学図書館（NLM）

Precision Therapy with Ceritinib for ALK-Rearranged Anaplastic Large Cell Lymphoma

Anaplastic large cell lymphoma (ALCL), a complex and aggressive cancer, often presents a challenging desert to navigate for patients and clinicians. This research, like a skilled explorer, delves into the potential of ceritinib, a targeted therapy, for treating ALK-rearranged ALCL. The researchers, like resourceful adventurers, conducted preclinical and clinical studies to investigate the efficacy of ceritinib in inhibiting the ALK fusion protein and inducing apoptosis in lymphoma cells. Their findings, like a precious oasis in the desert, reveal promising results, both in vitro and in vivo, suggesting that ceritinib may be a valuable tool for treating this aggressive cancer.

Ceritinib: A Precision Weapon Against ALK-Rearranged ALCL

The study's findings, like a potent antidote in the desert of cancer, demonstrate the potential of ceritinib as a precision therapy for ALK-rearranged ALCL. This targeted approach, like a well-aimed arrow, specifically targets the ALK fusion protein, potentially offering a more effective and less toxic treatment option for patients.

Implications for Health and Lifestyle

This research highlights the increasing importance of precision medicine in cancer treatment. By understanding the specific genetic alterations driving a cancer, like a unique fingerprint in the desert, clinicians can tailor treatments to individual patients, increasing the likelihood of successful outcomes and minimizing side effects.

Dr.Camel's Conclusion

This study reveals the potential of ceritinib to offer a beacon of hope for patients with ALK-rearranged ALCL. By targeting the specific genetic alteration driving this aggressive cancer, ceritinib may offer a precision weapon against this formidable foe, potentially transforming the landscape of ALCL treatment. This research, like a well-stocked oasis in the desert of cancer, offers a promising new direction for combating this disease.

Date :
  1. Date Completed 2021-10-29
  2. Date Revised 2022-02-24
Further Info :

Pubmed ID

34242968

DOI: Digital Object Identifier

PMC8271116

Related Literature

Article Analysis
・Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.